[1] Headache Classifification Committee of the International Headache Society (IHS) The International
Classifification of Headache Disorders, 3rd edition[J].
Cephalalgia, 2018, 38(1):1-211.
[2] Ran Y, Yin Z, Lian Y, et al. Gradually shifting clinical
phenomics in migraine spectrum: a cross-sectional,
multicenter study of 5438 patients[J]. J Headache Pain,
2022, 23(1):89.
[3] Dong Z, Di H, Dai W, et al. Application of ICHD II
criteria in a headache clinic of China[J]. PloS One,
2012, 7(12):e50898.
[4] Wang SJ, Fuh JL, Young YH, et al. Prevalence of
migraine in Taipei, Taiwan: a population-based survey[J].
Cephalalgia, 2000, 20(6):566-572.
[5] Global, regional, and national burden of neurological
disorders, 1990-2016: a systematic analysis for the Global
Burden of Disease Study 2016[J]. Lancet Neurol, 2019,
18(5):459-480.
[6] Ferrari MD, Goadsby PJ, Burstein R, et al. Migraine[J].
Nat Rev Dis primers, 2022, 8(1):2.
[7] Huang L, Juan Dong H, Wang X, et al . Duration
and frequency of migraines affect cognitive function:
evidence from neuropsychological tests and event-related
potentials[J]. J Headache Pain, 2017, 18(1):54.
[8] Wang SJ, Chung CS, Chankrachang S, et al. Migraine
disability awareness campaign in Asia: migraine assessment
for prophylaxis[J]. Headache, 2008, 48(9): 1356-1365.
[9] Liu R, Yu S, He M, et al. Health-care utilization for
primary headache disorders in China: a population-based
door-to-door survey[J]. J Headache Pain, 2013, 14(1):47.
[10] Li X, Zhou J, Tan G, et al. Diagnosis and treatment
status of migraine: a clinic-based study in China[J]. J
Neurol Sci, 2012, 315(1-2):89-92.
[11] 中华医学会疼痛学分会头面痛学组 , 中国医师协会神
经内科医师分会 疼痛和感觉障碍专委会 . 中国偏头痛
防治指南 [J]. 中国疼痛医学杂志 , 2016, 22(10):721-727.
[12] Lyngberg AC, Rasmussen BK, Jørgensen T, et al .
Incidence of primary headache: a Danish epidemiologic
follow-up study[J]. Am J Epidemiol, 2005, 161(11):
1066-1073.
[13] Baykan B, Ertas M, Karlı N, et al. Migraine incidence
in 5 years: a population-based prospective longitudinal
study in Turkey[J]. J Headache Pain, 2015, 16:103.
[14] Khil L, Pfaffenrath V, Straube A, et al. Incidence of
migraine and tension-type headache in three different
populations at risk within the German DMKG headache
study[J]. Cephalalgia, 2012, 32(4):328-336.
[15] Global, regional, and national burden of migraine
and tension-type headache, 1990-2016: a systematic
analysis for the Global Burden of Disease Study
2016[J]. Lancet Neurol, 2018, 17(11):954-976.
[16] Yu S, Liu R, Zhao G, et al. The prevalence and burden
of primary headaches in China: a population-based
door-to-door survey[J]. Headache, 2012, 52(4):582-591.
[17 ] Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis
and management of migraine in ten steps[J]. Nat Rev
Neurol, 2021, 17(8):501-514.
[18] Polderman TJ, Benyamin B, de Leeuw CA, et al. Meta
analysis of the heritability of human traits based on fififty
years of twin studies[J]. Nat Genet, 2015, 47(7): 702-709.
[19] Wang X, Yin Z, Lian Y, et al. Premonitory symptoms
in migraine from China: a multi-clinic study of 4821
patients[J]. Cephalalgia, 2021, 41(9):991-1003.
[20] He M, Yu S, Liu R, et al . Familial occurrence of
headache disorders: a population-based study in mainland
China[J]. Clin Neurol Neurosurg, 2016, 149: 143-146.
[21] Ashina M, Hansen JM, Do TP, et al. Migraine and the
trigeminovascular system-40 years and counting[J].
Lancet Neurol, 2019, 18(8):795-804.
[22] Olesen J, Burstein R, Ashina M, et al. Origin of pain
in migraine: evidence for peripheral sensitisation[J].
Lancet Neurol, 2009, 8(7):679-690.
[23] Schulte LH, May A. The migraine generator revisited:
continuous scanning of the migraine cycle over 30 days
and three spontaneous attacks[J]. Brain J, 2016, 139(Pt 7):
1987-1993.
[24] Ashina M. Migraine[J]. N Engl J Med, 2020, 383(19):
1866-1876.
[25] Brennan KC, Pietrobon D. A systems neuroscience
approach to migraine[J]. Neuron, 2018, 97(5):1004-1021.
[26] Dodick DW. Migraine[J]. Lancet, 2018, 391(10127):
1315-1330.
[27] Pi C, Tang W, Li Z, et al. Cortical pain induced by
optogenetic cortical spreading depression: from whole
brain activity mapping[J]. Mol Brain, 2022, 15(1):99.
[28] Li F, Qiu E, Dong Z, et al. Protection of flunarizine
on cerebral mitochondria injury induced by cortical
spreading depression under hypoxic conditions[J]. J
Headache Pain, 2011, 12(1):47-53.
[29] Zhang Q, Han X, Wu H, et al. Dynamic changes in
CGRP, PACAP, and PACAP receptors in the trigeminovascular system of a novel repetitive electrical stimulation
rat model: relevant to migraine[J]. Mol Pain, 2019,
15:1744806918820452.
[30] Han X, Ran Y, Su M, et al . Chronic changes in
pituitary adenylate cyclase-activating polypeptide and
related receptors in response to repeated chemical
dural stimulation in rats[J]. Mol Pain, 2017, 13:
1744806917720361.
[31] Chen N, Zhang J, Wang P, et al. Functional alterations
of pain processing pathway in migraine patients with
cutaneous allodynia[J]. Pain Med, 2015, 16(6):1211-
1220.
[32] Ma M, Zhang J, Chen N, et al. Exploration of intrinsic
brain activity in migraine with and without comorbid
depression[J]. J Headache Pain, 2018, 19(1):48.
[33] Chen Z, Chen X, Liu M, et al . Altered functional
connectivity of amygdala underlying the neuromechanism of migraine pathogenesis[J]. J Headache Pain,
2017, 18(1):7.
[34] Jia Z, Yu S, Tang W, et al. Altered functional connectivity
of the insula in a rat model of recurrent headache[J].
Mol Pain, 2020, 16:1744806920922115.
[35] Karsan N, Prabhakar P, Goadsby PJ. Characterising
the premonitory stage of migraine in children: a clinic
based study of 100 patients in a specialist headache
service[J]. J Headache Pain, 2016, 17(1):94.
[36] Schulte LH, May A. The migraine generator revisited:
continuous scanning of the migraine cycle over 30 days
and three spontaneous attacks[J]. Brain, 2016, 139(Pt 7):
1987-1993.
[37] Takeshima T, Ishizaki K, Fukuhara Y, et al. Population
based door-to-door survey of migraine in Japan: the
Daisen study[J]. Headache 2004, 44(1):8-19.
[38] Launer LJ, Terwindt GM, Ferrari MD. The prevalence
and characteristics of migraine in a population-based
cohort: the GEM study[J]. Neurology, 1999, 53(3):537-542.
[39] Zivadinov R, Willheim K, Jurjevic A, et al. Prevalence
of migraine in Croatia: a population-based survey[J].
Headache, 2001, 41(8):805-812.
[40] Kelman L. Pain characteristics of the acute migraine
attack[J]. Headache, 2006, 46(6):942-953.
[41] Zhang N, Chen CF. Clinical observation of the effect of
prophylaxis on allodynia in patients with migraine[J]. J
Pain Res, 2018, 11:2721-2728.
[42] Iljazi A. et al. Dizziness and vertigo during the
prodromal phase and headache phase of migraine: a
systematic review and meta-analysis[J]. Cephalalgia,
2020, 40(10):1095-1103.
[43] Al-Khazali HM, Younis S, Al-Sayegh Z, et al. Prevalence
of neck pain in migraine: a systematic review and metaanalysis[J]. Cephalalgia, 2022, 42(7):663-673.
[44] Giffin NJ, Lipton RB, Silberstein SD, et al . The
migraine postdrome: an electronic diary study[J]. Neurology, 2016, 87(3):309-313.
[45] 于生元 , 万琪 , 王武庆 , 等 . 前庭性偏头痛诊治专家共
识 (2018) [J]. 中国疼痛医学杂志 , 2018, 24(7):481-488.
[46] Diener HC, Tassorelli C, Dodick DW, et al. Guidelines
of the International Headache Society for controlled
trials of acute treatment of migraine attacks in adults:
fourth edition[J]. Cephalalgia, 2019, 39(6):687-710.
[47] Ailani J, Burch RC, Robbins MS. The American
Headache Society Consensus Statement: update on
integrating new migraine treatments into clinical
practice[J]. Headache, 2021, 61(7):1021-1039.
[48] Diener HC, Gaul C, Lehmacher W, et al. Aspirin,
paracetamol (acetaminophen) and caffeine for the
treatment of acute migraine attacks: a systemic review
and meta-analysis of randomized placebo-controlled
trials[J]. Eur J Neurol, 2022, 29(1):350-357.
[49] Reuter U, McClure C, Liebler E, et al. Non-invasive
neuromodulation for migraine and cluster headache:
a systematic review of clinical trials[J]. J Neurol
Neurosurg Psychiatry, 2019, 90(7):796-804.
[50] Derry S, Rabbie R, Moore RA. Diclofenac with or
without an antiemetic for acute migraine headaches
in adults[J]. Cochrane Database Syst Rev, 2013(4):
CD008783.
[51] Kirthi V, Derry S, Moore RA. Aspirin with or without
an antiemetic for acute migraine headaches in adults[J].
Cochrane Database Syst Rev, 2013(4):CD008041.
[52] Law S, Derry S, Moore RA. Naproxen with or without
an antiemetic for acute migraine headaches in adults[J].
Cochrane Database Syst Rev, 2013(10):CD009455.
[53] Rabbie R, Derry S, Moore RA. Ibuprofen with or
without an antiemetic for acute migraine headaches
in adults[J]. Cochrane Database Syst Rev, 2013(4):
CD008039.
[54] Derry S, Moore RA. Paracetamol (acetaminophen)
with or without an antiemetic for acute migraine
headaches in adults[J]. Cochrane Database Syst Rev,
2013(4):CD008040.
[55] Cameron C, Kelly S, Hsieh SC, et al. Triptans in the
acute treatment of migraine: a systematic review and
network meta-analysis[J]. Headache, 2015, 55 Suppl
4:221-235.
[56] Law S, Derry S, Moore RA. Sumatriptan plus naproxen
for the treatment of acute migraine attacks in adults[J].
Cochrane Database Syst Rev, 2016, 4(4):CD008541.
[57] Diener HC. The Risks or Lack Thereof of Migraine
Treatments in Vascular Disease. Headache 2020, 60(3):
649-653.
[58] Eadie MJ. Ergot of rye-the fifirst specifific for
migraine[J]. J Clin Neurosci, 2004, 11(1):4-7.
[59] Dahlof C. Placebo-controlled clinical trials with
ergotamine in the acute treatment of migraine[J].
Cephalalgia, 1993, 13(3):166-171.
[60] Clemow DB, Johnson KW, Hochstetler HM, et al. Lasmiditan mechanism of action-review of a selective
5-HT(1F) agonist[J]. J Headache Pain, 2020, 21(1):71.
[61] Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan
is an effffective acute treatment for migraine: a phase 3
randomized study[J]. Neurology, 2018, 91(24):e2222-
e2232.
[62] Shapiro RE, Hochstetler HM, Dennehy EB, et al .
Lasmiditan for acute treatment of migraine in patients
with cardiovascular risk factors: post-hoc analysis
of pooled results from 2 randomized, double-blind,
placebo-controlled, phase 3 trials[J]. J Headache Pain,
2019, 20(1):90.
[63] Rau JC, Navratilova E, Oyarzo J, et al. Evaluation
of LY573144 (lasmiditan) in a preclinical model of
medication overuse headache[J]. Cephalalgia, 2020,
40(9):903-912.
[64] Negro A, Martelletti P. Novel synthetic treatment
options for migraine[J]. Expert Opin Pharmacother,
2021, 22(7):907-922.
[65] Durham PL. CGRP-receptor antagonists-a fresh approach to migraine therapy?[J]. New Engl J Med, 2004,
350(11):1073-1075.
[66] van Hoogstraten WS, MaassenVanDenBrink A. The
need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse[J]. J Headache Pain, 2019, 20(1):54.
[67] Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for
the treatment of migraine[J]. New Engl J Med, 2019,
381(23):2230-2241.
[68] Lipton RB, Dodick DW, Ailani J, et al . Effect of
ubrogepant vs placebo on pain and the most bothersome
associated symptom in the acute treatment of migraine:
the ACHIEVE II randomized clinical trial[J]. JAMA,
2019, 322(19):1887-1898.
[69] Lipton RB, Croop R, Stock EG, et al. Rimegepant, an
oral calcitonin gene-related peptide receptor antagonist,
for migraine[J]. New Engl J Med, 2019, 381(2):142-149.
[70] American Headache Society. The american headache
society position statement on integrating new migraine
treatments into clinical practice[J]. Headache, 2019,
59(1):1-18.
[71] Derry CJ, Derry S, Moore RA. Sumatriptan (oral route
of administration) for acute migraine attacks in adults[J].
Cochrane Database Syst Rev, 2012(2):CD008615.
[72] Bird S, Derry S, Moore RA. Zolmitriptan for acute
migraine attacks in adults[J]. Cochrane Database Syst
Rev, 2014(5):CD008616.
[73] Tepper SJ, Kori SH, Goadsby PJ, et al. MAP0004,
orally inhaled dihydroergotamine for acute treatment of
migraine: effiffifficacy of early and late treatments[J].
Mayo Clin Proc, 2011, 86(10):948-955.
[74] Worthington I, Pringsheim T, Gawel MJ, et al. Canadian
headache society guideline: acute drug therapy for
migraine headache[J]. Can J Neurol Sci, 2013, 40(5
Suppl 3):S1-S80.
[75] Orlova YY, Mehla S, Chua AL. Drug safety in episodic
migraine management in adults part 1: acute treatments[J].
Curr Pain Headache Rep, 2022, 26(7):481-492.
[76] Black E, Khor KE, Kennedy D, et al. Medication use
and pain management in pregnancy: a critical review[J].
Pain Pract,2019, 19(8):875-899.
[77] Burch R. Epidemiology and treatment of menstrual
migraine and migraine during pregnancy and lactation:
a narrative review[J]. Headache 2020, 60(1):200-216.
[78] Marchenko A, Etwel F, Olutunfese O, et al. Pregnancy
outcome following prenatal exposure to triptan
medications: a meta-analysis[J]. Headache, 2015, 55(4):
490-501.
[79] Spielmann K, Kayser A, Beck E, et al. Pregnancy
outcome after anti-migraine triptan use: a prospective
observational cohort study[J]. Cephalalgia, 2018, 38(6):
1081-1092.
[80] Amundsen S, Nordeng H, Fuskevåg OM, et al. Transfer
of triptans into human breast milk and estimation of
infant drug exposure through breastfeeding[J]. Basic
Clin Pharmacol Toxicol, 2021, 128(6):795-804.
[81] Steiner TJ, Jensen R, Katsarava Z, et al . Aids to
management of headache disorders in primary care (2nd
edition): on behalf of the european headache federation
and lifting the burden: the global campaign against
ceadache[J]. J Headache Pain, 2019, 20(1):57.
[82] Stubberud A, Flaaen NM, McCrory DC, et al .
Flunarizine as prophylaxis for episodic migraine: a
systematic review with meta-analysis[J]. Pain, 2019,
160(4):762-772.
[83] Linde M, Mulleners WM, Chronicle EP, et al. Topiramate
for the prophylaxis of episodic migraine in adults[J].
Cochrane Database Syst Rev, 2013(6): CD010610.
[84] Linde M, Mulleners WM, Chronicle EP, et al. Valproate
(valproic acid or sodium valproate or a combination of the
two) for the prophylaxis of episodic migraine in adults[J].
Cochrane Database Syst Rev, 2013(6):CD010611.
[85] Frank F, Ulmer H, Sidoroffff V, et al. CGRP-antibodies,
topiramate and botulinum toxin type A in episodic
and chronic migraine: a systematic review and metaanalysis[J]. Cephalalgia, 2021, 41(11-12):1222-1239.
[86] Linde M, Mulleners WM, Chronicle EP, et al .
Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic
migraine in adults[J]. Cochrane Database Syst Rev,
2013(6):CD010608.
[87] Jackson JL, Kuriyama A, Kuwatsuka Y, et al. Betablockers for the prevention of headache in adults, a
systematic review and meta-analysis[J]. PLoS One,
2019, 14(3):e0212785.
[88] Linde M, Mulleners WM, Chronicle EP, et al. Gabapentin or pregabalin for the prophylaxis of episodic
migraine in adults[J]. Cochrane Database Syst Rev,
2013(6):CD010609.
[89] Di Trapani G, Mei D, Marra C, et al. Gabapentin in the
prophylaxis of migraine: a double-blind randomized
placebo-controlled study[J]. Clin Ter, 2000, 151(3):145-
148.
[90] Mathew NT, Rapoport A, Saper J, et al. Efficacy of
gabapentin in migraine prophylaxis[J]. Headache, 2001,
41(2):119-128.
[91] Hesami O, Shams MR, Ayazkhoo L, et al. Comparison
of pregabalin and sodium valproate in migraine
prophylaxis: a randomized double-blinded study[J].
Iran Pharm Res, 2018, 17(2):783-789.
[92] Xu XM, Liu Y, Dong MX, et al. Tricyclic antidepressants for preventing migraine in adults[J]. Medicine
(Baltimore), 2017, 96(22):e6989.
[93] Banzi R, Cusi C, Randazzo C, et al. Selective serotonin
reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention
of migraine in adults[J]. Cochrane Database Syst Rev,
2015, 4:CD002919.
[94] Ozyalcin SN, Talu GK, Kiziltan E, et al. The effiffifficacy
and safety of venlafaxine in the prophylaxis of
migraine[J]. Headache, 2005, 45(2):144-152.
[95] Shaterian N, Shaterian N, Ghanaatpisheh A, et al. Botox (Onabotulinumtoxin A) for treatment of migraine
symptoms: a systematic review[J]. Pain Res Manag,
2022, 2022:3284446.
[96] Herd CP, Tomlinson CL, Rick C, et al. Cochrane systematic review and meta-analysis of botulinum toxin
for the prevention of migraine[J]. BMJ Open, 2019,
9(7):e027953.
[97] Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant
for preventive treatment of migraine: a phase 2/3,
randomised, double-blind, placebo-controlled trial[J].
Lancet, 2021, 397(10268):51-60.
[98] Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for
the preventive treatment of migraine[J]. N Engl J Med,
2021, 385(8):695-706.
[99] Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Effiffifficacy
and tolerability of erenumab in patients with episodic
migraine in whom two-to-four previous preventive
treatments were unsuccessful: a randomised, doubleblind, placebo-controlled, phase 3b study[J]. Lancet,
2018, 392(10161):2280-2287.
[100] Ashina M, Goadsby PJ, Reuter U, et al. Longterm
efficacy and safety of erenumab in migraine prevention:
results from a 5-year, open-label treatment phase of
a randomized clinical trial[J]. Eur J Neurol, 2021,
28(5):1716-1725.
[101] Yu S, Kim BK, Wang H, et al. A phase 3, randomised,
placebo-controlled study of erenumab for the
prevention of chronic migraine in patients from Asia:
the DRAGON study[J]. J Headache Pain, 2022,
23(1):146.
[102] Dodick DW, Silberstein SD, Bigal ME, et al. Effffect
of fremanezumab compared with placebo for
prevention of episodic migraine: a randomized clinical
trial[J]. JAMA, 2018, 319(19):1999-2008.
[103] Silberstein SD, Dodick DW, Bigal ME, et al .
Fremanezumab for the preventive treatment of chronic
migraine[J]. New Engl J Med, 2017, 377(22):2113-
2122.
[104] Yang CP, Zeng BY, Chang CM, et al. Comparative
effectiveness and tolerability of the pharmacology of
monoclonal antibodies targeting the calcitonin generelated peptide and its receptor for the prevention
of chronic migraine: a network meta-analysis of
randomized controlled trials[J]. Neurotherapeutics,
2021, 18(4):2639-2650.
[105] Stauffffer VL, Dodick DW, Zhang Q, et al. Evaluation of
galcanezumab for the prevention of episodic migraine:
the EVOLVE-1 randomized clinical trial[J]. JAMA
Neurol, 2018, 75(9):1080-1088.
[106] Hu B, Li G, Li X, et al. Galcanezumab in episodic
migraine: the phase 3, randomized, double-blind,
placebo-controlled PERSIST study[J]. J Headache
Pain, 2022, 23(1):90.
[107] Mulleners WM, Kim BK, Láinez MJA, et al. Safety
and efficacy of galcanezumab in patients for whom
previous migraine preventive medication from two to
four categories had failed (CONQUER): a multicentre,
randomised, double-blind, placebo-controlled, phase
3b trial[J]. Lancet Neurol, 2020, 19(10):814-825.
[108] Silvestro M, Tessitore A, Orologio I, et al. Galcanezumab
effect on ''whole pain burden'' and multidimensional
outcomes in migraine patients with previous
unsuccessful treatments: a real-world experience[J]. J
Headache Pain, 2022, 23(1):69.
[109] Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and
safety of eptinezumab in patients with chronic migraine:
PROMISE-2[J]. Neurology, 2020, 94(13): e1365-e1377.
[110] Ashina M, Saper J, Cady R, et al. Eptinezumab in
episodic migraine: a randomized, double-blind, placebocontrolled study (PROMISE-1)[J]. Cephalalgia, 2020,
40(3):241-254.
[111] Stovner LJ, Linde M, Gravdahl GB, et al. A comparative
study of candesartan versus propranolol for migraine
prophylaxis: a randomised, triple-blind, placebocontrolled, double cross-over study[J]. Cephalalgia,
2014, 34(7):523-532.
[112] Tronvik E, Stovner LJ, Helde G, et al. Prophylactic
treatment of migraine with an angiotensin II receptor
blocker: a randomized controlled trial[J]. JAMA, 2003,
289(1):65-69.
[113] Schrader H, Stovner LJ, Helde G, et al. Prophylactic
treatment of migraine with angiotensin converting enzyme
inhibitor (lisinopril): randomised, placebo controlled,
crossover study[J]. BMJ, 2001, 322(7277): 19-22.
[114] Sándor PS, Di Clemente L, Coppola G, et al .
Efficacy of coenzyme Q10 in migraine prophylaxis: a
randomized controlled trial[J]. Neurology, 2005, 64(4):
713-715.
[115] Sazali S, Badrin S, Norhayati MN, et al. Coenzyme
Q10 supplementation for prophylaxis in adult patients
with migraine-a meta-analysis[J]. BMJ Open, 2021,
11(1):e039358.
[116] Schoenen J, Jacquy J, Lenaerts M. Effectiveness
of high-dose riboflavin in migraine prophylaxis. A
randomized controlled trial[J]. Neurology, 1998, 50(2):
466-470.
[117] MacLennan SC, Wade FM, Forrest KM, et al. Highdose riboflavin for migraine prophylaxis in children: a
double-blind, randomized, placebo-controlled trial[J].
J Child Neurol, 2008, 23(11):1300-1304.
[118] Bruijn J, Duivenvoorden H, Passchier J, et al. Mediumdose riboflavin as a prophylactic agent in children with
migraine: a preliminary placebo-controlled, randomised,
double-blind, cross-over trial[J]. Cephalalgia, 2010,
30(12):1426-1434.
[119] Karimi N, Razian A, Heidari M. The efficacy of
magnesium oxide and sodium valproate in prevention
of migraine headache: a randomized, controlled,
double-blind, crossover study[J]. Acta Neurologica
Belgica, 2021, 121(1):167-173.
[120] Köseoglu E, Talaslioglu A, Gönül AS, et al. The effects
of magnesium prophylaxis in migraine without aura[J].
Magnes Res, 2008, 21(2):101-108.
[121] Wang F, Van Den Eeden SK, Ackerson LM, et al. Oral
magnesium oxide prophylaxis of frequent migrainous
headache in children: a randomized, double-blind,
placebo-controlled trial[J]. Headache, 2003, 43(6):601-
610.
[122] Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis
of migraine with oral magnesium: results from a prospective,
multi-center, placebo-controlled and double-blind
randomized study[J]. Cephalalgia, 1996, 16(4):257-263.
[123] Amundsen S, Nordeng H, Nezvalová-Henriksen K,
et al. Pharmacological treatment of migraine during
pregnancy and breastfeeding[J]. Nat Rev Neurol, 2015,
11(4):209-219.
[124] Yakoob MY, Bateman BT, Ho E, et al. The risk of
congenital malformations associated with exposure
to β-blockers early in pregnancy: a meta-analysis[J].
Hypertension, 2013, 62(2):375-381.
[125] Pringsheim T, Davenport W, Mackie G, et al. Canadian
headache society guideline for migraine prophylaxis[J].
Practice Guideline, 2012, 39(2 Suppl 2): S1-59.
[126] Lassen D, Ennis ZN, Damkier P. First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of
major congenital malformations: a systematic review[J].
Basic Clin Pharmacol Toxicol, 2016, 118(1):32-36.
[127] Ohman I, Vitols S, Luef G, et al. Topiramate kinetics
during delivery, lactation, and in the neonate: preliminary
observations[J]. Epilepsia, 2002, 43(10): 1157-1160.
[128] Luedtke K, Allers A, Schulte LH, et al. Efficacy of
interventions used by physiotherapists for patients
with headache and migraine-systematic review and
metaanalysis[J]. Cephalalgia, 2016, 36(5):474-492.
[129] Hindiyeh NA, Zhang N, Farrar M, et al. The role of
diet and nutrition in migraine triggers and treatment:
a systematic literature review[J]. Headache, 2020,
60(7):1300-1316.
[130] Liu H, Wang L, Chen C, et al. Association between
dietary niacin intake and migraine among american
adults: national health and nutrition examination
survey[J]. Nutrients, 2022, 14(15):3052.
[131] Yu S, Ran Y, Xiao W, et al. Treatment of migraines
with Tianshu capsule: a multi-center, double-blind,
randomized, placebo-controlled clinical trial[J]. BMC
Complement Altern Med, 2019, 19(1):370.
[132] Yu S, Ran Y, Wan Q, et al. Efficacy and safety of
toutongning capsule in patients with migraine: a multicenter, randomized, double-blind, placebocontrolled
trial[J]. J Altern Complement Med, 2019, 25(12):1215-
1224.
[133] Yu S, Hu Y, Wan Q, et al. A multicenter, doubleblind,
randomized, placebo-controlled trial to evaluate the
efficacy and safety of duliang soft capsule in patients
with chronic daily headache[J]. Evid Based Complement Alternat Med, 2015, 2015:694061.
[134] 贾敏鲁 , 张允岭 , 廖星 , 等 . 口服中成药治疗偏头痛
的网状 Meta 分析 [J]. 中国中药杂志 , 2020, 45(21):15.
[135] Li Y, Liang F, Yang X, et al. Acupuncture for treating
acute attacks of migraine: a randomized controlled
trial[J]. Headache, 2009, 49(6):805-816.
[136] Diener HC, Kronfeld K, Boewing G, et al. Efficacy
of acupuncture for the prophylaxis of migraine: a
multicentre randomised controlled clinical trial[J].
Lancet Neurol, 2006, 5(4):310-316.
[137] Xu S, Yu L, Luo X, et al. Manual acupuncture versus
sham acupuncture and usual care for prophylaxis
of episodic migraine without aura: multicentre,
randomised clinical trial[J]. BMJ, 2020, 368:m697.
[138] Zhao L, Chen J, Li Y, et al. The long-term effect of
acupuncture for migraine prophylaxis: a randomized
clinical trial[J]. JAMA Intern Med, 2017, 177(4):508-515.
[139] Fan SQ, Jin S, Tang TC, et al . Effiffifficacy of
acupuncture for migraine prophylaxis: a trial sequential
metaanalysis[J]. J Neurol, 2021, 268(11):4128-4137.
[140] Chou DE, Shnayderman Yugrakh M, Winegarner D,
et al. Acute migraine therapy with external trigeminal
neurostimulation (ACME): a randomized controlled
trial[J]. Cephalalgia, 2019, 39(1):3-14.
[141] Schoenen JE. Migraine prevention with a supraorbital
transcutaneous stimulator: a randomized controlled
trial[J]. Neurology, 2016, 86(2):201-202.
[142] Tassorelli C, Grazzi L, de Tommaso M, et al .
Noninvasive vagus nerve stimulation as acute therapy
for migraine: the randomized PRESTO study[J].
Neurology, 2018, 91(4):e364-e373.
[143] Starling AJ, Tepper SJ, Marmura MJ, et al. A multicenter,
prospective, single arm, open label, observational study
of sTMS for migraine prevention (ESPOUSE Study)[J].
Cephalalgia, 2018, 38(6):1038-1048.
[144] Yarnitsky D, Dodick DW, Grosberg BM, et al .
Remote electrical neuromodulation (REN) relieves
acute migraine: a randomized, double-blind,
placebocontrolled, multicenter trial[J]. Headache,
2019, 59(8):1240-1252.
[145] Rapoport AM, Bonner JH, Lin T, et al . Remote
electrical neuromodulation (REN) in the acute
treatment of migraine: a comparison with usual care
and acute migraine medications[J]. J Headache Pain,
2019, 20(1):83.
[146] Deng Y, Zheng M, He L, et al . A head-to-head
comparison of percutaneous mastoid electrical
stimulator and supraorbital transcutaneous stimulator
in the prevention of migraine: a prospective, randomized
controlled study[J]. Neuromodulation, 2020,
23(6):770-777.
[147] Wilkinson D, Ade KK, Rogers LL, et al. Preventing
episodic migraine with caloric vestibular stimulation:
a randomized controlled trial[J]. Headache, 2017,
57(7):1065-1087.
[148] Penning S, Schoenen J. A survey on migraine attack
treatment with the CEFALY® device in regular users[J]. Acta Neurol Belg, 2017, 117(2):547-549.
[149] Danno D, Iigaya M, Imai N, et al. The safety and
preventive effects of a supraorbital transcutaneous
stimulator in Japanese migraine patients[J]. Sci Rep,
2019, 9(1):9900.
[150] Silberstein SD, Calhoun AH, Lipton RB, et al. Chronic
migraine headache prevention with noninvasive vagus
nerve stimulation: the EVENT study[J]. Neurology,
2016, 87(5):529-538.
[151] Liu Y, Dong Z, Wang R, et al. Migraine prevention
using difffferent frequencies of transcutaneous
occipital nerve Stimulation: a randomized controlled
trial[J]. J Pain, 2017, 18(8):1006-1015.
[152] Bhola R, Kinsella E, Giffin N, et al. Single-pulse
transcranial magnetic stimulation (sTMS) for the acute
treatment of migraine: evaluation of outcome data for
the UK post market pilot program[J]. J Headache Pain,
2015, 16:535.
[153] Ailani J, Rabany L, Tamir S, et al. Real-world analysis
of remote electrical neuromodulation (REN) for
the acute treatment of migraine[J]. Front Pain Res
(Lausanne), 2021, 2:753736.
[154] Bae JY, Sung HK, Kwon NY, et al . Cognitive
behavioral therapy for migraine headache: a systematic
review and meta-analysis[J]. Medicina (Kaunas), 2021,
58(1):44.
[155] Andrasik F. Biofeedback in headache: an overview of
approaches and evidence[J]. Cleve Clin J Med, 2010,
77 Suppl 3:S72-76.
[156] Cousins S, Ridsdale L, Goldstein LH, et al. A pilot
study of cognitive behavioural therapy and relaxation
for migraine headache: a randomised controlled
trial[J]. J Neurol, 2015, 262(12):2764-2772.
[157] Lip PZY, Lip GYH. Patent foramen ovale and
migraine attacks: a systematic review[J]. Am J Med,
2014, 127(5):411-420.
[158] Mattle HP, Evers S, Hildick-Smith D, et al .
Percutaneous closure of patent foramen ovale in
migraine with aura, a randomized controlled trial[J].
Eur Heart J, 2016, 37(26):2029-2036.
[159] Pristipino C, Germonpré P, Toni D, et al. European
position paper on the management of patients with
patent foramen ovale. Part II-Decompression sickness,
migraine, arterial deoxygenation syndromes and select
high-risk clinical conditions[J]. Eur Heart J, 2021,
42(16):1545-1553.
[160] Tobis JM, Charles A, Silberstein SD, et al .
Percutaneous closure of patent foramen ovale in
patients with migraine: the PREMIUM trial[J]. J Am
Coll Cardiol, 2017, 70(22):2766-2774.
